Scientific Programme
Thursday 23rd September 2010
11.00 – 13.00 Registration for meeting and hotels plus a light lunch
13.00 Welcome and Conference Overview (Jo Bradwell, Birmingham, UK)
13.05 – 14.30 Review lectures
Chair: Jo Bradwell
13.05 The Monoclonal Proteins: A Brief History (Bob Kyle, Mayo Clinic, USA)
13.35 Serum Free Light Chain (sFLC) guidelines for monoclonal gammopathies (Brian Durie, Cedars-Sinai, USA)
13.55 Serum FLC assay: Technical considerations (Hugh Carr-Smith, Birmingham, UK)
14.10 Role of sFLC assays in the laboratory (Jerry Katzmann, Mayo Clinic, USA)
14.30 Coffee / Tea
15.00 – 16.00 Free light chains (FLCs) and the kidney
Chair: Paul Cockwell
15.00 Use of high cut-off haemodialysis for the treatment of myeloma kidney: Worldwide experience to date (Colin Hutchison, Birmingham, UK)
15.20 EuLITE Trial: results to date (Mark Cook, Birmingham, UK)
15.45 Polyclonal FLC and Chronic Kidney Disease (Stephanie Stringer, Birmingham, UK)
16.00 – 19.00 Poster Session: Wine and cheese reception
Friday 24th September 2010
09.00 Poster prizes announcements
09.10 - 10.50 Diseases associated with monoclonal free light chains
Chair: Bob Kyle
09.10 AL amyloidosis – Role of FLC assay in risk estimation (Shaji Kumar, Mayo Clinic, USA)
09.30 FLCs in the amyloidosis clinic (Philip Hawkins, London, UK)
09.50 Serum Free Light Chains in Chronic Lymphocytic Leukaemia (Guy Pratt, Birmingham, UK)
10.10 Serum Free Light Chains in Non-Hodgkin Lymphoma (Matthew Maurer / Thomas Witzig USA)
10.30 Progressing serum immune abnormalities in myelomagenesis (Ola Landgren, Bethesda, USA)
10.50 Coffee / Tea
11.15 – 12.40 Diseases associated with elevated polyclonal free light chains I
Chair: Philip Hawkins
11.15 Concepts (Graham Mead, Birmingham, UK)
11.35 Non-clonal serum immunoglobin free light chains (FLC) as markers of overall survival (Angela Dispenzieri, Mayo Clinic, USA)
12.00 Polyclonal free light chain elevation and mortality in the German Heinz Nixdorf Recall study (Jan Dürig, Essen, Germany)
12.20 Circluating serum free light chains as predictors of AIDS lymphoma and beyond (Ola Landgren, Bethesda, USA)
12.40 – 13.40 Lunch
13.40 – 14.40 Diseases associated with elevated polyclonal free light chains II
Chair: Angela Dispenzieri
13.40 Hepatitis C and lymphoma development (Benjamin Terrier, Paris, France)
14.00 Free light chains of immunoglobulins as disease activity markers in autoimmune diseases (JE Gottenberg, Paris, France)
14.20 Clinical and biological relevance of serum Free Light Chains (sFLC) assessment in patients with Hodgkin's lymphoma (Antonio Pinto, Naples, Italy)
14.40 Coffee / Tea
15.00 - 17.00 Hevylite
Chair: Jo Bradwell, Bob Kyle, Brian Durie
15.00 Concepts (Jo Bradwell, Birmingham, UK)
15.20 Diagnostic role of Heavy / Light Chain Analysis (Stephen Harding, Birmingham, UK)
15.40 Monitoring multiple myeloma patients with heavy / light chain antibodies for IgA and IgG (Heinz Ludwig, Vienna, Austria)
16.00 Prognostic role of myeloma (Hérve Avet-Loiseau, Nantes, France)
16.20 Prognostic role of Hevylite in MGUS (Jerry Katzmann, Mayo Clinic, USA)
16.40 Case studies (Graham Mead, UK)
17.00 Summary and close (Jo Bradwell, UK, Bob Kyle, USA, Brian Durie, USA)
19.00 Drinks Reception at the Roman Baths followed by Conference Dinner
